Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00123643
Status:
COMPLETED
Last Update Posted:
2013-07-15
First Post:
2005-07-21
Brief Title:
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
Sponsor:
St Paul Heart Clinic
Organization:
St Paul Heart Clinic
Study Overview
Official Title:
Comparison of Rosiglitazone Versus Glyburide on Vascular Structure and Function in Type 2 Diabetic Patients
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the vascular effects of two commonly used diabetes medications rosiglitazone and glyburide in type 2 diabetic patients
Detailed Description:
Rosiglitazone and glyburide are two commonly used diabetic medications that have both been shown to be effective in controlling blood glucose levels Since they work in different ways they may have different effects on the health of the blood vessels This study will assess which medication is better at improving the health of the arteries separate from the blood glucose lowering effects Artery health will be assessed non-invasively by ultrasound Certain markers of atherosclerosis found in the blood will also be measured
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None